SCHEMBL24257579

SCHEMBL24257579

Cc1c(-c2cnn(CC(C)C)c2)cnc(C#N)c1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.40
KDM5A P29375 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.38
PDK2 Q15119 1/20 0.38
ADORA2B P29275 3/20 0.35
ADORA3 P0DMS8 2/20 0.35
AXL P30530 2/20 0.35
TYRO3 Q06418 2/20 0.35
MERTK Q12866 2/20 0.35
ADORA2A P29274 2/20 0.35
ADORA1 P30542 2/20 0.35
PIK3CD O00329 1/20 0.35
MAPK1 P28482 1/20 0.35
PRKCI P41743 1/20 0.34
NAMPT P43490 1/20 0.34
ATP4A P20648 1/20 0.33
ATP4B P51164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
JAK2 O60674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257581 0.86 RET (0.38) RETKDM5APDK2ATP4AATP4B
SCHEMBL24257678 0.82 GRM4 (0.50) KDM5AMAPK1GRM4
SCHEMBL24257760 0.82 JAK2 (0.41) RETPDK2ADORA2BADORA3AXL
SCHEMBL24257812 0.79 GRM5 (0.46) KDM5AADORA2BADORA2AADORA1ATP4A
SCHEMBL24257536 0.78 GRM4 (0.44) KDM5AGRM4
SCHEMBL24257766 0.77 IRAK4 (0.43) RETKDM5AKDM5BIRAK4PDK2
SCHEMBL30546888 0.77 CYP11B1 (0.42) MAPK1ATP4AATP4BL3MBTL1
SCHEMBL24257687 0.77 CYP11B1 (0.42) MAPK1ATP4AATP4BL3MBTL1
SCHEMBL24257777 0.76 MAPT (0.42) MAPK1ATP4AATP4BL3MBTL1
SCHEMBL24257578 0.76 CYP11B1 (0.47) MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 RET 2282/4885KDM5A 199/4885KDM5B 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.